Abstract
Amivantamab, a novel, fully human bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and MET, is being explored as a monotherapy in non-small cell lung cancer (NSCLC) within the CHRYSALIS study (NCT02609776), and has received Breakthrough Therapy Designation for the treatment of patients with EGFR exon 20 insertion disease, after prior treatment with platinum chemotherapy. Given the bispecific nature of amivantamab, its role in patients with MET exon 14 skipping (METex14) mutations is being explored (MET-2 cohort) in patients both naïve to and refractory to other available MET therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
